Abeona Therapeutics Inc. | Mutual Funds
Mutual Funds that own Abeona Therapeutics Inc.
SPDR S&P Biotech ETF
2,717,404
5.67%
6,990
0.72%
09/06/2018
Fidelity Select Health Care Portfolio
1,700,000
3.55%
0
0.35%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,211,873
2.52%
0
0.2%
07/31/2018
T Rowe Price New Horizons Fund
1,137,928
2.37%
634,200
0.07%
06/30/2018
Fidelity Series Small Cap Opportunities Fund
851,715
1.78%
52,200
0.2%
04/30/2018
Fidelity Advisor Health Care Fund
760,000
1.59%
0
0.34%
07/31/2018
Vanguard Total Stock Market Index Fund
756,664
1.58%
0
0%
07/31/2018
iShares Russell 2000 ETF
645,461
1.35%
-345
0.02%
09/06/2018
Fidelity Small Cap Growth Fund
635,025
1.33%
635,025
0.21%
04/30/2018
Fidelity Health Care Central Investment Portfolio
550,000
1.14%
110,000
0.27%
03/31/2018
| Address |
1330 Avenue of the Americas
New York New York 10019
United States
|
|
Employees
|
- |
| Website |
http://www.abeonatherapeutics.com |
| Updated |
07/08/2019 |
| Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Dallas, TX. |
